Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CD40 | P25942 | 1/20 | 0.40 |
| ▸ | CD40LG | P29965 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21857610 | 0.85 | CA9 (0.46) | CA9CA1CA2MEN1KMT2A | |
| SCHEMBL9635973 | 0.76 | KMT2A (0.47) | HTTMAPTMEN1KMT2AHPGD | |
| SCHEMBL30842286 | 0.76 | CA12 (0.42) | CA9CD40CD40LGMAPTMEN1 | |
| SCHEMBL21857932 | 0.75 | CA12 (0.41) | CA9CA1CA2MEN1KMT2A | |
| SCHEMBL30461559 | 0.73 | CA12 (0.47) | CA9CA1CA2MEN1KMT2A | |
| SCHEMBL29018091 | 0.73 | CA12 (0.47) | CA9CA1CA2MEN1KMT2A | |
| SCHEMBL8514648 | 0.72 | TTR (0.56) | CA9CA1CA2CD40CD40LG | |
| SCHEMBL30950399 | 0.72 | TTR (0.56) | CA9CA1CA2CD40CD40LG | |
| SCHEMBL9634985 | 0.68 | TSHR (0.40) | MAPTMEN1KMT2AGAAHPGD | |
| SCHEMBL18045522 | 0.67 | POLB (0.55) | CA9CA1CA2HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200277256-A1 | SELECTIVE SHIP INHIBITORS FOR TREATING DISEASE | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2020-09-03 | — | — | US | claimed |
| WO-2020081852-A1 | SELECTIVE SHIP INHIBITORS FOR TREATING DISEASE | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2020-04-23 | — | — | WO | claimed |
| US-11952328-B2 | Selective ship inhibitors for treating disease | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-04-09 | — | — | US | disclosed |
| US-20200277256-A1 | SELECTIVE SHIP INHIBITORS FOR TREATING DISEASE | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2020-09-03 | — | — | US | disclosed |
| US-20200277256-A1 | SELECTIVE SHIP INHIBITORS FOR TREATING DISEASE | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277256-A1 | SELECTIVE SHIP INHIBITORS FOR TREATING DISEASE | PPP5C, MTMR1, PPM1G | CA9 4553/4885CA1 4745/4885CA2 3640/4885 |
| US-11952328-B2 | Selective ship inhibitors for treating disease | PPM1A, MTMR1, PPM1B | CA9 4526/4885CA1 4813/4885CA2 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.